Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lubna Ahmed

London, U.K
From Scrip website: Lubna Ahmed joined the Scrip editorial team in 2015 as a shiny new graduate in human biology and journalism, an interesting combination and perfect prologue to a career with Scrip. She is particularly interested in digital medicine and technology, social media, and who is moving where within the pharma industry. Lubna has a surprisingly large Twitter following for a non-celebrity, and when she isn't reading, writing or editing pharma-related news and analysis, she can be found eating chocolate and composing tweets to keep the Twittersphere entertained.
Set Alert for Articles By Lubna Ahmed

Latest From Lubna Ahmed

Appointments: Gyroscope, Urovant, Horizon, Modus, Allied Minds And Adherium

This week's roundup includes CEO appointments by Gyroscope Therapeutics, Urovant Sciences and Nevoii Pharmaceuticals, in addition to various other high-level appointments by companies including, Horizon Pharma, Veloxis Pharmaceuticals, Modus Therapeutics and Adherium.

Appointments BioPharmaceutical

Boehringer Taps Gubra For Early-Stage Obesity Deal

Boehringer Ingelheim has signed a collaboration with Denmark-based Gubra focusing on the development of peptides to treat obesity, with Gubra to receive up to €250m in upfront and potential milestone payments.

Deals Metabolic Disorders

Appointments: Piramal Pharma, Oxeia, Artios Eyevensys and Bone Therapeutics

This week's roundup includes a new CEO for Oxeia, in addition to various other high-level appointments by Piramal Pharma Solutions, Bone Therapeutics, Kiadis and biOasis. Artios Pharma also welcomes AstraZeneca's former senior director bioscience, oncology to its team.

Appointments BioPharmaceutical

Rigontec Buy Adds RNA Tech To Merck & Co IO Portfolio

Merck & Co. adds to its immuno-oncology pipeline with the acquisition of Rigontec for an upfront payment of €115m, with the three-year-old company offering Merck a unique approach to immunotherapy and a lead candidate currently in Phase I/II trials, the first of its kind in human studies.

ImmunoOncology Deals

Deal Watch: Inventiva Expands Collaborations With Boehringer, AbbVie

French biotech expands fibrosis partnership with Boehringer Ingelheim, and a co-development pact with AbbVie around ROR gamma inverse agonists. Helsinn signs on to detail Novartis' Zykadia in the US.

Deals M & A

Appointments: Almirall, Axial, Therachon, Theranexus, Carrick and Karolinksa

This week's roundup includes Almirall's appointment of a former Sanofi employee as CEO and various other high-level appointments by Axial, Therachon, Theranexus and Karolinska.

Appointments BioPharmaceutical
See All